Assess the efficacy of a thrombolytic agent in reducing infarct size and thereby improving ventricular function and subsequent morbidity and mortality. The primary endpoint will be total mortality during the follow up period. Secondary endpoints include determination of the: effect of thrombolytic therapy on left ventricular ejection fraction;proportion of patients suspected of having myocardial infarction with complete versus incomplete occlusion of the infarct related artery; time limits for successful reperfusion including differences according to the route of administration; and frequency and severity of adverse effects of intracoronary and intravenous administration of thrombolytic agents in patients with acute infarction.
| Berger, P B; Ruocco Jr, N A; Ryan, T J et al. (1993) Frequency and significance of right ventricular dysfunction during inferior wall left ventricular myocardial infarction treated with thrombolytic therapy (results from the thrombolysis in myocardial infarction [TIMI] II trial). The TIMI Research Group. Am J Cardiol 71:1148-52 |
| Ruocco Jr, N A; Bergelson, B A; Jacobs, A K et al. (1992) Invasive versus conservative strategy after thrombolytic therapy for acute myocardial infarction in patients with antecedent angina. A report from Thrombolysis in Myocardial Infarction Phase II (TIMI II). J Am Coll Cardiol 20:1445-51 |
| Berger, P B; Ruocco Jr, N A; Ryan, T J et al. (1992) Incidence and prognostic implications of heart block complicating inferior myocardial infarction treated with thrombolytic therapy: results from TIMI II. J Am Coll Cardiol 20:533-40 |
| Berger, P B; Ryan, T J (1990) Inferior myocardial infarction. High-risk subgroups. Circulation 81:401-11 |
